PHASE I & CLINICAL PHARMACOKINETICS - ANTI-CANCER AGENTS

第一阶段

• 批准号: 3607820
• 负责人: MARK J RATAIN
• 金额: $ 25.45万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-05-01 至 1995-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3607820
• 关键词: antineoplastics; chemical information system; clinical trials; drug adverse effect; drug metabolism; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology

The specific objectives of this contract are: 1) to define the acute toxicities of new anticancer agents in patients with advanced cancer; 2) to redefine the acute toxicities and pharmacokinetics of anticancer administered in combination with agents to modulate toxicity or antitumor effect; 3) to provide information on the pharmacokinetic characteristics (absorption, distribution, metabolism and elimination) and pharmacodynamics of selected antitumor agents; and 4) to determine a treatment regimen suitable for evaluation of antitumor activity in Phase II trials.

本合同的具体目标是：1)定义急性 新抗肿瘤药物对晚期癌症患者的毒性；2) 重新定义抗癌药物的急性毒性和药代动力学 与药物联合使用以调节毒性或 抗肿瘤作用；3)提供药代动力学信息 特征(吸收、分布、代谢和消除) 和选定的抗肿瘤药物的药效学；4)确定 一种适合于评价人卵巢癌抗肿瘤活性的治疗方案 第二阶段试验。